“We are excited that the first data readout from our pivotal phase 3 COMP360 program in treatment resistant depression continues on track with top-line 6-week data expected next quarter,” said Kabir Nath, Chief Executive Officer. “Building on last year’s promising phase 2a data in PTSD and the resources now available from the January financing, we are advancing plans to develop a late-stage clinical program for PTSD with the goal of getting COMP360 to patients as quickly as possible. The need for a new approach to treatment remains significant in TRD and PTSD and we believe COMP360 represents a novel treatment option in these mental health conditions.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPS:
- Positive Outlook for COMPASS Pathways Amid Psychedelic Acceptance and Strategic Investment Opportunity
- Compass Pathways initiated with a Buy at Stifel
- Psychedelic: Exclusive talk with biotech company Enveric Biosciences
- Compass Pathways price target lowered to $45 from $60 at H.C. Wainwright
- Psychedelic: Relmada acquires neurosteroid from Asarina